# Pelthos Therapeutics Inc. (PTHS) · Edgar & Edgarette company card

> Pelthos Therapeutics (PTHS) reported revenue of $17 million in FY2025, operating margin -193% against a -15.8% median for biological products, (no diagnostic substances), equity 29.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1919246 · fiscal year ended 2025-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/PTHS) · [JSON](https://www.pops4.com/boards/company/PTHS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $17M |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -193.1% (prior year -Infinity%) |
| Net margin | -257.9% |
| Operating cash flow | −$23M |
| Capital spending | $99,000 |
| Free cash flow | −$23M |
| Cash | $18M |
| Long-term debt | — |
| Total assets | $130M |
| Total equity | $39M |
| Equity ÷ assets | 29.8% |
| Return on equity | -111.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -1.47 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · filed earlier statements no longer to be relied on, auditor change in the last 12 months; operating cash flow was negative; operating loss: a margin of -193.1% in FY2025

## Edgarette's reading

Exposure: revenue $16.8M (FY2025). Experience: one year on record; operating margin -193.1%, up from null. Soundness: equity 29.8% of assets, return on equity -111.4%. Credibility: 2 audited years, little weight, marked down from moderate: on 2026-08-13 the company said earlier statements should no longer be relied on (8-K Item 4.02), and no 10-K has been filed since. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -193.1% against a -15.8% median.

## Health Watch, last 12 months

- Item 4.02 Earlier statements no longer to be relied on: 1, latest 2026-08-13 ([filing](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000110/0001919246-26-000110-index.htm))
- Item 4.01 Auditor change: 1, latest 2026-05-21 ([filing](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000078/0001919246-26-000078-index.htm))
- Item 5.02 Director or officer change: 6, latest 2026-10-30 ([filing](https://www.sec.gov/Archives/edgar/data/1919246/000110465926120457/0001104659-26-120457-index.htm))

## Recent filings

- 10-Q · filed 2026-11-12 · [filing](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000135/0001919246-26-000135-index.htm)
- 8-K · filed 2026-11-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000134/0001919246-26-000134-index.htm)
- 8-K · filed 2026-10-30 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modifications to Rights of Security Holders; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1919246/000110465926120457/0001104659-26-120457-index.htm)
- 8-K · filed 2026-10-01 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000125/0001919246-26-000125-index.htm)
- DEF 14A · filed 2026-08-18 · [filing](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000120/0001919246-26-000120-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000113/0001919246-26-000113-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001919246.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1919246

## Cite

POPS4, Edgar & Edgarette: Pelthos Therapeutics Inc. (PTHS) company card, from the company's own SEC filings, accessed 2026-11-16, https://www.pops4.com/boards/company/PTHS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

